Boots – shoes – and leggings
Patent
1994-12-13
1997-12-30
Voeltz, Emanuel T.
Boots, shoes, and leggings
364578, G06F 1750
Patent
active
057037922
ABSTRACT:
A method and system for selecting molecules or molecular parts for screening. A base set of molecules on which chemical tests are to be performed is defined, and once defined, the base set may be extended by selecting molecules which are determined to maximize the diversity of the extended set. Diversity of a set of molecules is measured by reference to steric, electrostatic, and hydrogen bonding features of the set of 3D conformational shapes which each molecule in the set may take on. Each molecule is assigned a measure of incremental (added) diversity with respect to the base set of molecules on which chemical tests are to be performed. To do this, for each new molecule, a set of conformations is defined, and for each conformation, a measure of dissimilarity from each conformation of those molecules in the base set is defined. The molecule's measure of added diversity is responsive to a closest match between the any conformation of that molecule and any conformation of any molecule already in the base set. This measure of dissimilarity is determined by means of a continuous function minimization technique, such as gradient descent or simulated annealing. The base set may then be extended with the molecule whose measure of added diversity is greatest.
REFERENCES:
patent: 5025388 (1991-06-01), Cramer, III et al.
patent: 5167009 (1992-11-01), Skeirik
patent: 5260882 (1993-11-01), Blanco et al.
patent: 5265030 (1993-11-01), Skolnick et al.
patent: 5574656 (1996-11-01), Agrafiotis et al.
Kearsley et al. "Flexibases: A Way to Enhance the Use of Molecular Docking Methods", Journal of Computer-Aided Molecular Design v. 8 pp. 565-582, 1994.
T.A. Andrea, et al., Applications of Neural Networks in Quantitative Structure-Activity Relationship of Dihydrofolate Reductase Inhibitors, Journal of Medicinal Chemistry, vol. 34, No. 9, 1991, pp. 2824-2836.
Good, et al., Structure-Activity Relationships from Molecular Similarity Matrices, Journal of Medicinal Chemistry, vol. 36, No. 4, Feb. 19, 1993, pp. 433-438.
Aoyama, et al., Neural Networks Applied to Quantitative Structure-Activity Relationship Analysis, Journal of Medicinal Chemistry, 1990, vol. 33, No. 9, pp. 2583-2590.
Aoyama, et al., Obtaining the Correlation Indices Between Drug Activity and Structural Parameters Using a Neural Network, Chemical Pharmaceutical Bulletin, vol. 39, No. 2, pp. 372-378, 1991.
Oinuma, et al., Neural Networks Applied to Structure-Activity Relationships, Journal of Medicinal Chemistry, vol. 33, No. 3, 1990, pp. 905-908.
Viswanadhan, et al., Mapping the Binding Site of the Nucleoside Transporter Protein: A 3D-QSAR Study, Biochemica et Biophysica Acta., 1039 (1990) 356-366.
Ghose, et al., Use of Physicochemical Parameters in Distance Geometry and Related There-Dimensional Quantitative Structure-Activity Relationships: A Demonstration Using Escherichia coli Dihydrofolate Reductase Inhibitors, Journal of Medical Chemistry, vol. 28, No. 3, 1985, pp. 333-346.
Smellie, et al., Fast Drug-Receptor Mapping by Site-Directed Distances: A Novel Method of Predicting New Pharmacological Leads, J. Chem. Inf. Comput. Sci., vol. 31, No. 3, 1991, pp. 386-392.
Cramer, III et al., Comparative Molecular Field Analysis (COMFA), J. Am. Chem. Soc., vol. 110, No. 18, 1988, pp. 5959-5967.
Crippen, et al., Distance Geometry and Molecular Conformation, Research Studies Press Ltd., 8 Ligand Binding, pp. 361-429.
Hopfinger, A QSAR Investigation of Dihydrofolate Reductase Inhibition by Baker Triazines Based Upon Molecular Shape Analysis, J. Am. Chem. Soc., 1980, 102, 7196-7206.
Doweyko, The Hypothetical Active Site Lattice. An Approach to Modelling Active Sites from Data on Inhibitor Molecules, Journal of American Chemistry, 1988, 31 (7), pp. 1396-1406.
Simon, et al., Mapping of Dihydrofolate-Reductase Receptor Site by Correlation With Minimal Topological (steric) Differences, J. Theor. Biol., 1977, 66, pp. 485-495.
Crippen, Deduction of Binding Site Structure From Ligand Binding Data, Annals New York Academy of Sciences, vol. 439, 1984, pp. 1-11.
Boulu, et al., Voronoi Binding Site Models: Calculation of Binding Modes and Influence of Drug Binding Data Accuracy, Journal of Computational Chemistry, 10 (5), 673-682 (1989).
Crippen, Voronoi Binding Site Models, Journal of Computational Chemistry 8 (7), 943-955 (1987).
Boulu, et al., Voronoi Binding Site Model of a Polycyclic Aromatic Hydrocarbon Binding Protein, J. Med. Chem., 1990, 33, 771-775.
Blankley, Introduction: A Review of QSAR Methodology, Academic Press, Inc., 1983, pp. 1-17.
Nicklaus, et al., QSAR of Conformationally Flexible Molecules: Comparative Molecular Field Analysis of Protein-Tyrosine Kinase Inhibitors, Journal of Computer-Aided Molecular Design, 6 (1992) 487-504.
Arris Pharmaceutical Corporation
Kemper M.
Voeltz Emanuel T.
LandOfFree
Three dimensional measurement of molecular diversity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Three dimensional measurement of molecular diversity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Three dimensional measurement of molecular diversity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-208748